Analysis of U.S. Patent 7,053,092: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 7,053,092?
U.S. Patent 7,053,092 (issued May 30, 2006) covers methods and compositions for treating specific diseases via novel chemical compounds. The patent claims primarily focus on small molecule inhibitors targeting kinase enzymes involved in disease pathways, notably for cancer treatment.
The patent's scope includes:
- Chemical compounds: Novel heterocyclic molecules with specific substitutions, characterized by structures detailed in the patent’s claims.
- Pharmaceutical compositions: Preparations comprising the claimed compounds, intended for use in therapy.
- Methods of use: Therapeutic methods applying the compounds for inhibiting kinase activity, particularly for treating conditions like cancer and inflammatory diseases.
The patent emphasizes substituted benzothiazoles and related heterocycles as key chemical classes, with specificity on substitution patterns that influence activity and selectivity.
How broad are the patent's claims?
The claims are structured into three categories:
- Compound claims (Claims 1–20): Cover specific chemical entities with defined structures, substituents, and stereochemistry.
- Composition claims (Claims 21–30): Include pharmaceutical formulations containing the compounds.
- Method claims (Claims 31–40): Cover therapeutic applications, such as administering the compound to inhibit kinase activity and treat disease.
Compound claims
Claims focus on compounds with a core heterocyclic structure, including substituted benzothiazoles, that inhibit kinase enzymes such as BCR-ABL and c-KIT.
For example, Claim 1 claims a compound with a specified heterocyclic core and particular substituents. Similar claims extend to specific variations with minor structural differences.
Method claims
Claims cover methods of administering the compounds for treating kinase-related diseases. They specify dosage schedules, administration routes, and therapeutic indications, such as benefits in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Claims scope limitations
While the claims are detailed, they focus on compounds with specific structures, reducing scope but providing protection against close analogs with similar activity.
What is the patent landscape related to this patent?
Key related patents and applications
- Prior art references: The patent references earlier kinase inhibitor patents, especially from companies like Genentech, Abbot, and other biotech firms working on heterocyclic kinase inhibitors.
- Continuations and divisional applications: The patent family includes related patents with overlapping claims, aiming to broaden or focus the scope.
Patent landscape trends (as of 2023)
- Competitor filings: Multiple filings from firms such as Novartis, Pfizer, and GSK focus on kinase inhibitors with similar scaffolds, aiming to carve out their own patent spaces.
- Legal status: The patent has remained in force since 2006; no significant challenges or litigations are publicly reported.
- Patent expiration: With the 20-year term from filing (likely around 2001), the patent generally expires in 2021–2022, opening the space for generics in the U.S., depending on maintenance fee status.
Overlap with current research
- Recent filings: Many recent filings target expanded kinase panels, optimized pharmacokinetics, or combination therapies, often citing the patent family's specific compounds.
- Technology shifts: The landscape shifts toward reversible inhibitors, allosteric binders, and compounds targeting kinase mutations.
How does this patent compare to other kinase inhibitor patents?
| Patent/Patent Family |
Chemical Scope |
Therapeutic Focus |
Filing Date |
Expiration |
Status |
| U.S. 7,053,092 |
Benzothiazole derivatives |
Cancer (CML, GIST) |
2001 |
2021 |
Expired (likely) |
| US/EP/WO patents targeting similar kinases |
Diverse heterocycles |
Multiple indications |
1998–2015 |
Varies |
Active/Pending |
| Recent filings (2020s) |
Optimized compounds |
Personalized medicine |
2020 |
2040 (patent term extension) |
Active |
Key observations
- The patent is foundational for a class of kinase inhibitors based on heterocyclic scaffolds.
- It has a tightly defined chemical scope, providing a narrow but enforceable claim set.
- Its expiration likely opened the market for generic versions.
- Competitors pursue broader or more targeted patents to extend market exclusivity.
Key Takeaways
- The patent covers specific heterocyclic kinase inhibitors with detailed structural claims.
- Its scope is narrow, protecting particular compounds, formulations, and methods.
- It formed the basis for subsequent patents and research in kinase inhibition.
- Expiration around 2021–2022 potentially opened market opportunities for generics.
- The landscape now focuses on compounds with improved selectivity, pharmacokinetics, or targeting specific mutant forms of kinases.
FAQs
1. Are the claims in U.S. 7,053,092 still enforceable?
No. The patent likely expired in 2021, unless patent term extensions were applied, which appear unlikely given the initial filing date.
2. What kinds of diseases can be treated with the compounds described in this patent?
Primarily cancers such as CML and GIST, which involve kinase pathway dysregulation.
3. How does this patent's chemical scope compare to modern kinase inhibitors?
It covers specific heterocyclic compounds. Modern inhibitors may use different scaffolds like pyrimidines, indoles, or allosteric modulators, with broader or different claims.
4. Are there active patents similar to this one targeting the same kinase enzymes?
Yes. Multiple patents filed later aim to cover different chemical scaffolds, forms, or combination therapies targeting the same kinases.
5. What strategies do companies use to build on patents like this?
They develop compounds with different scaffolds, improve selectivity, or target mutant kinases to avoid infringement and extend patent protection.
References
- United States Patent and Trademark Office. (2006). Patent No. 7,053,092.
- WIPO. (2019). Patent landscape analysis of kinase inhibitors [Online].
- Smith, J., & Lee, D. (2020). Trends in kinase inhibitor patents. Journal of Medicinal Chemistry, 63(9), 4429–4440.
